These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 35404188)

  • 21. Monotonicity conditions for avoiding counterintuitive decisions in basket trials.
    Baumann L; Krisam J; Kieser M
    Biom J; 2022 Jun; 64(5):934-947. PubMed ID: 35692061
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multi-stage enrichment and basket trial designs with population selection.
    Li W; Zhao J; Li X; Chen C; Beckman RA
    Stat Med; 2019 Dec; 38(29):5470-5485. PubMed ID: 31621949
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives.
    Brookes ST; Whitley E; Peters TJ; Mulheran PA; Egger M; Davey Smith G
    Health Technol Assess; 2001; 5(33):1-56. PubMed ID: 11701102
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Accurate p-values for adaptive designs with binary endpoints.
    Heritier S; Lloyd CJ; Lô SN
    Stat Med; 2017 Jul; 36(17):2643-2655. PubMed ID: 28470713
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An automation-based adaptive seamless design for dose selection and confirmation with improved power and efficiency.
    Cui L; Zhan T; Zhang L; Geng Z; Gu Y; Chan IS
    Stat Methods Med Res; 2021 Apr; 30(4):1013-1025. PubMed ID: 33459183
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimizing trial design in pharmacogenetics research: comparing a fixed parallel group, group sequential, and adaptive selection design on sample size requirements.
    Boessen R; van der Baan F; Groenwold R; Egberts A; Klungel O; Grobbee D; Knol M; Roes K
    Pharm Stat; 2013; 12(6):366-74. PubMed ID: 24214896
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increasing trial efficiency by early reallocation of placebo nonresponders in sequential parallel comparison designs: application to antidepressant trials.
    Boessen R; Knol MJ; Groenwold RH; Grobbee DE; Roes KC
    Clin Trials; 2012 Oct; 9(5):578-87. PubMed ID: 23060319
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multiplicity and flexibility in clinical trials.
    Brannath W; Koenig F; Bauer P
    Pharm Stat; 2007; 6(3):205-16. PubMed ID: 17674349
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An analysis of adaptive design variations on the sequential parallel comparison design for clinical trials.
    Mi MY; Betensky RA
    Clin Trials; 2013 Apr; 10(2):207-15. PubMed ID: 23283576
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design and analysis of a 2-year parallel follow-up of repeated ivermectin mass drug administrations for control of malaria: Small sample considerations for cluster-randomized trials with count data.
    Jackson CL; Colborn K; Gao D; Rao S; Slater HC; Parikh S; Foy BD; Kittelson J
    Clin Trials; 2021 Oct; 18(5):582-593. PubMed ID: 34218684
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Type-II generalized family-wise error rate formulas with application to sample size determination.
    Delorme P; de Micheaux PL; Liquet B; Riou J
    Stat Med; 2016 Jul; 35(16):2687-714. PubMed ID: 26914402
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sequential monitoring of covariate adaptive randomized clinical trials with sample size re-estimation.
    Yu J; Lai D
    Contemp Clin Trials; 2019 Dec; 87():105874. PubMed ID: 31678412
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimized multi-stage designs controlling the false discovery or the family-wise error rate.
    Zehetmayer S; Bauer P; Posch M
    Stat Med; 2008 Sep; 27(21):4145-60. PubMed ID: 18444249
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A group sequential, response-adaptive design for randomized clinical trials.
    Karrison TG; Huo D; Chappell R
    Control Clin Trials; 2003 Oct; 24(5):506-22. PubMed ID: 14500050
    [TBL] [Abstract][Full Text] [Related]  

  • 35. On the efficiency of adaptive sample size design.
    Cui L; Zhang L
    Stat Med; 2019 Mar; 38(6):933-944. PubMed ID: 30450621
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adaptive design clinical trials and trial logistics models in CNS drug development.
    Wang SJ; Hung HM; O'Neill R
    Eur Neuropsychopharmacol; 2011 Feb; 21(2):159-66. PubMed ID: 20933373
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bayesian basket trial design with exchangeability monitoring.
    Hobbs BP; Landin R
    Stat Med; 2018 Nov; 37(25):3557-3572. PubMed ID: 29984488
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A new basket trial design based on clustering of homogeneous subpopulations.
    Krajewska M; Rauch G
    J Biopharm Stat; 2021 Jul; 31(4):425-447. PubMed ID: 34236938
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Power and sample size when multiple endpoints are considered.
    Senn S; Bretz F
    Pharm Stat; 2007; 6(3):161-70. PubMed ID: 17674404
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Bayesian basket trial design accounting for uncertainties of homogeneity and heterogeneity of treatment effect among subpopulations.
    Asano J; Hirakawa A
    Pharm Stat; 2020 Nov; 19(6):975-1000. PubMed ID: 32779393
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.